NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq: NRXP) announced that subsidiary HOPE Therapeutics is the first commercial site to deploy Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach clinic.
The AI-guided platform delivers sub-millimetric, image-guided TMS for major depressive disorder and other neurological conditions, supports HOPE's interventional psychiatry network, and aligns with a planned NRX-101 plus robotic-enabled TMS clinical trial in depression and suicidality.
AI-generated analysis. Not financial advice.
Positive
- First commercial deployment of Zeta TMS Navigation System at a HOPE clinic
- AI-guided, sub-millimetric TMS targeting with setup times under two minutes per session
- Technology aligns with planned NRX-101 plus robotic-enabled TMS clinical trial
- Enhances HOPE's interventional psychiatry platform across its clinic network
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
NRXP gained 33.85%, while the only momentum-scanner peer listed (INKT) moved down. Other biotech peers showed a mix of modest gains and losses, suggesting this move was company-specific rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | Q1 2026 earnings | Positive | -5.0% | Reported sharply reduced net loss and cash update with pipeline progress. |
| May 14 | Earnings call notice | Neutral | +8.8% | Announced timing and access details for upcoming Q1 2026 results call. |
| May 07 | Trial FDA clearance | Positive | +0.3% | Received FDA clearance for phase 2/3 trial of NRX-101 with TMS in depression. |
| May 05 | Manufacturing launch | Positive | +1.3% | Initiated first commercial GMP manufacturing for preservative-free ketamine product. |
| Apr 22 | FDA review letter | Positive | +1.7% | Received positive FDA Discipline Review Letter on preservative-free ketamine ANDA. |
Positive regulatory and pipeline updates have generally seen modest positive alignment, while one earnings release drew a negative reaction despite operational progress.
Recent news shows a steady build of catalysts. On Apr 22, NRXP reported positive FDA feedback on its preservative-free ketamine ANDA with a 1.69% gain. Manufacturing initiation on May 5 and FDA clearance for the NRX-101 TMS trial on May 7 saw small positive moves. An earnings-date notice on May 14 coincided with an 8.81% rise, but Q1 results on May 18 led to a 5.03% drop despite a sharply lower net loss. Today’s clinic-navigation deployment fits the ongoing TMS-focused strategy.
Regulatory & Risk Context
An effective S-3/A shelf filed on Dec 12, 2025 permits NRx Pharmaceuticals to offer up to $150,000,000 in various securities, with $78,644,060 carried forward from a prior registration. Shelf usage is currently reported as 0, indicating capacity remains available for future capital raises.
Market Pulse Summary
This announcement highlights expansion of NRx’s interventional psychiatry platform as HOPE Therapeutics became the first commercial site for Zeta’s FDA-cleared TMS navigation system, adding AI-guided, sub-millimetric targeting and setup times under two minutes. It connects directly to earlier TMS-related NRX-101 trial plans. Investors may track subsequent clinical data, utilization across HOPE clinics, and how these developments integrate with the company’s broader CNS pipeline and capital-raising capacity under its shelf registration.
Key Terms
transcranial magnetic stimulation medical
tms medical
major depressive disorder medical
computer vision technical
mri medical
ct scan medical
fiducial markers technical
hyperbaric oxygen therapy medical
AI-generated analysis. Not financial advice.
- Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions
- Installation complements HOPE's interventional psychiatry platform and aligns with NRx's previously announced clinical trial of NRX-101 in combination with robotic-enabled TMS
WEST PALM BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its wholly-owned subsidiary, HOPE Therapeutics, Inc. ("HOPE"), has become the first commercial site to deploy Zeta Surgical's FDA-cleared Zeta TMS Navigation System. The system has been installed at HOPE's West Palm Beach, Florida clinic, where it will be used to deliver high-precision, image-guided Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions.
"Being selected as the first commercial site for Zeta's FDA-cleared TMS Navigation System validates the integrated treatment model we are building at HOPE," said Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals and HOPE Therapeutics. "Zeta's AI-driven image guidance brings neurosurgical-grade targeting precision into our outpatient clinics, and it sets the stage for our planned trial of NRX-101 in combination with robotic-enabled TMS in patients with depression and suicidality."
TMS is a non-invasive therapy widely used for treatment-resistant depression, which affects approximately one-third of patients with major depression. The clinical efficacy of TMS depends heavily on the accurate targeting of specific neural circuits. The Zeta TMS Navigation System uses proprietary RealTrack™ computer vision and artificial intelligence to continuously align a patient's MRI or CT scan with their facial anatomy in real time, delivering sub-millimetric precision and reducing setup times to under two minutes per session without the need for conventional fiducial markers.
The deployment complements HOPE's broader interventional psychiatry platform, which includes ketamine and Spravato® delivery, TMS, Hyperbaric Oxygen Therapy, and other neuroplastic therapies offered across the HOPE network of clinics. It also aligns with NRx's previously announced clinical trial program of NRX-101 (oral D-cycloserine/lurasidone) in combination with robotic-enabled TMS for patients with depression and suicidality, which is planned to be conducted across a leading US academic teaching hospital, three HOPE Therapeutics clinics, and two military treatment facilities.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetic stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve remission from treatment-resistant depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
